Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MABank

Financiado

Creation of a GLP bank of immune-privileged, immortal mesoangioblasts to treat m...

Creation of a GLP bank of immune-privileged, immortal mesoangioblasts to treat monogenic, recessive diseases of muscle and connective tissue Stem cells led to effective cures for diseases of blood and epithelia. However, in the case of diseases affecting muscles, connective tissue or brain, significant challenges persist for expansion of a sufficient number of correcte... ver más

28/02/2025

OSR

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-08-31

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS Objective:Objectives:The ERC Proof of Concept Grants aim at facilitating exploration of the commerci...

I+D

Cerrada hace 1 año

0% 100% 100%

2 Participantes

OSR

115.00K€ | Lider

DAY ONE

35.00K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

UniMab Immune privileged immortal myogenic stem cells for gene th... 2M€ Cerrado

SAF2012-40149-C02-01 ESTUDIO PRECLINICO PARA EVALUAR CELULAS MESENQUIMALES HUMANA... 70K€ Cerrado

EQC2019-005948-P Unidad para investigación y desarrollo en terapia celular av... 143K€ Cerrado

SAF2012-33404 TERAPIA COMBINADA BASADA DOS TIPOS CELULARES Y DOS SISTEMAS... 140K€ Cerrado

SAF2010-18792 GENERATION OF INDUCED PLURIPOTENT STEM CELL LINES FROM MUSCU... 109K€ Cerrado

EIN2019-103058 PASOS PRELIMINARES PARA EL DESARROLLO DE UNA TERAPIA FRENTE... 13K€ Cerrado

Duración del proyecto: 17 meses Fecha Inicio: 2023-08-31
Fecha Fin: 2025-02-28

Líder del proyecto

OSPEDALE SAN RAFFAELE SRL No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Stem cells led to effective cures for diseases of blood and epithelia. However, in the case of diseases affecting muscles, connective tissue or brain, significant challenges persist for expansion of a sufficient number of corrected cells, delivery and engraftment. Even when these problems will be solved the prospective per-patient cost of the treatment (up to 2M$) will make such therapies unsustainable for NHS. We developed protocols of cell therapy using mesoangioblasts (Mabs), vessel associated progenitors that, despite promising results in animal models, showed modest efficacy in patients. To address this, we transplanted autologous dystrophic Mabs expressing a small nuclear RNA engineered to skip dystrophin exon 51, that enters and corrects also neighboring nuclei of the multinucleated muscle fiber, thus bringing dystrophic production to therapeutic levels. A Phase I/IIa trial is currently running. Even in case of success, the cost would remain prohibitive. Through the ongoing ERC ADG 884952-UniMab, we are completing the development of immortal, immune-privileged Mabs from dystrophic patients thanks to genome editing of HLA and the expression of tolerogenic proteins. In this PoC project we will produce universal Mabs from healthy donors and will study the feasibility of producing and storing a large amount of universal Mabs through a bank of universal donor Mabs from healthy patients, ready to be corrected for the specific genetic mutation and injected into the patient following the motto one serve many. Available cells, a GMP-grade lentivector, expressing the wt cDNA of the mutated gene and a mouse model for pre-clinical tests would be sufficient to start a trial even for extremely rare diseases that currently lack even the hope of a therapy. This work will enable the business exploitation of the MABANK technology, by creating a company with a GMP biobank that may operate internally and make cells available to clinicians and Biotech companies.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores